{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T19:27:16Z","timestamp":1772220436293,"version":"3.50.1"},"reference-count":39,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["NICK17K0"],"award-info":[{"award-number":["NICK17K0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["NICK18P0"],"award-info":[{"award-number":["NICK18P0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["NICK20Y2-SVC"],"award-info":[{"award-number":["NICK20Y2-SVC"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["NICK20Y2-OUT"],"award-info":[{"award-number":["NICK20Y2-OUT"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["NICK23A1"],"award-info":[{"award-number":["NICK23A1"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL146228"],"award-info":[{"award-number":["R01HL146228"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Routine screening for nontuberculous mycobacterial (NTM) lung disease is dependent on sputum cultures. This is particularly challenging in the cystic fibrosis (CF) population due to reduced sputum production and low culture sensitivity. Biomarkers of infection that do not rely on sputum may lead to earlier diagnosis, but validation trials require a unique prospective design.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The rationale of this trial is to investigate the utility of urine lipoarabinomannan (LAM) as a test to identify people with CF with a new positive NTM culture. We hypothesize that urine LAM is a sensitive, non-invasive screening test with a high negative predictive value to identify individuals with a relatively low risk of having positive NTM sputum culture.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study design<\/jats:title>\n                    <jats:p>This is a prospective, single-center, non-randomized observational study in adults with CF, 3 years of negative NTM cultures, and no known history of NTM positive cultures. Patients are followed for two year-long observational periods with the primary endpoint being a positive NTM sputum culture within a year of a positive urine LAM result and a secondary endpoint of a positive NTM sputum culture within 3 years of a positive urine LAM result. Study implementation includes remote consent and sample collection to accommodate changes from the COVID-19 pandemic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This report describes the study design of an observational study aimed at using a urine biomarker to assist in the diagnosis of NTM lung infection in pwCF. If successful, urine LAM could be used as an adjunct to traditional sputum cultures for routine NTM screening, and replace cultures in low-risk individuals unable to produce sputum.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0309191","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T16:08:18Z","timestamp":1741622898000},"page":"e0309191","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prospective Analysis of urINe LAM to Eliminate NTM Sputum Screening (PAINLESS) study: Rationale and trial design for testing urine lipoarabinomannan as a marker of NTM lung infection in cystic fibrosis"],"prefix":"10.1371","volume":"20","author":[{"given":"Kara M.","family":"Calhoun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Armantrout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6400-0378","authenticated-orcid":true,"given":"Katie","family":"Poch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Caceres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie K.","family":"Lovell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8097-6059","authenticated-orcid":true,"given":"Kenneth C.","family":"Malcolm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Vestal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noel","family":"Rysavy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan","family":"Manzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Aboellail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphi","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerry A.","family":"Nick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,3,10]]},"reference":[{"issue":"4","key":"pone.0309191.ref001","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"DE Griffith","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"pone.0309191.ref002","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/cid\/ciaa1125","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: An official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"71","author":"CL Daley","year":"2020","journal-title":"Clinical Infectious Diseases"},{"issue":"Suppl 1","key":"pone.0309191.ref003","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1136\/thoraxjnl-2015-207360","article-title":"US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis","author":"RA Floto","year":"2016","journal-title":"Thorax"},{"issue":"7","key":"pone.0309191.ref004","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1513\/AnnalsATS.201709-727OC","article-title":"Epidemiology of pulmonary nontuberculous mycobacterial sputum positivity in patients with cystic fibrosis in the United States, 2010-2014","volume":"15","author":"J Adjemian","year":"2018","journal-title":"Ann Am Thorac Soc"},{"issue":"5","key":"pone.0309191.ref005","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1164\/rccm.201405-0884OC","article-title":"Nontuberculous mycobacteria among patients with cystic fibrosis in the United States: screening practices and environmental risk","volume":"190","author":"J Adjemian","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"pone.0309191.ref006","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.ccm.2022.06.010","article-title":"Nontuberculous Mycobacterial Infections in Cystic Fibrosis","volume":"43","author":"SL Martiniano","year":"2022","journal-title":"Clin Chest Med"},{"issue":"1","key":"pone.0309191.ref007","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1513\/AnnalsATS.201309-310OC","article-title":"Clinical significance of a first positive nontuberculous mycobacteria culture in cystic fibrosis","volume":"11","author":"SL Martiniano","year":"2014","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"pone.0309191.ref008","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.mimet.2005.01.010","article-title":"Comparison of NaOH-N-acetyl cysteine and sulfuric acid decontamination methods for recovery of mycobacteria from clinical specimens","volume":"62","author":"PCAM Buijtels","year":"2005","journal-title":"J Microbiol Methods"},{"issue":"4","key":"pone.0309191.ref009","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0272-2712(02)00018-5","article-title":"Diagnosis of nontuberculous mycobacterial infections","volume":"22","author":"BA Brown-Elliott","year":"2002","journal-title":"Clin Lab Med"},{"issue":"10","key":"pone.0309191.ref010","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/S1473-3099(06)70602-8","article-title":"Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review","volume":"6","author":"KR Steingart","year":"2006","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"pone.0309191.ref011","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1007\/s10096-002-0760-y","article-title":"Improved decontamination method for recovering mycobacteria from patients with cystic fibrosis","volume":"21","author":"F-C Bange","year":"2002","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"10","key":"pone.0309191.ref012","doi-asserted-by":"crossref","DOI":"10.1172\/JCI167957","article-title":"Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist","volume":"133","author":"D Nichols","year":"2023","journal-title":"J Clin Invest"},{"key":"pone.0309191.ref013","volume-title":"Cystic Fibrosis Foundation Patient Registry: 2022 Annual Data Report","author":"B Marshall","year":"2023"},{"key":"pone.0309191.ref014","doi-asserted-by":"crossref","first-page":"102276","DOI":"10.1016\/j.tube.2022.102276","article-title":"Culture independent markers of nontuberculous mycobacterial (NTM) lung infection and disease in the cystic fibrosis airway","volume":"138","author":"JA Nick","year":"2023","journal-title":"Tuberculosis (Edinb)"},{"issue":"11","key":"pone.0309191.ref015","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens12111281","article-title":"Collected thoughts on mycobacterial lipoarabinomannan, a cell envelope lipoglycan","volume":"12","author":"J Torrelles","year":"2023","journal-title":"Pathogens"},{"issue":"6","key":"pone.0309191.ref016","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1183\/09031936.00025711","article-title":"Diagnosing tuberculosis with urine lipoarabinomannan: systematic review and meta-analysis","volume":"38","author":"J Minion","year":"2011","journal-title":"Eur Respir J"},{"key":"pone.0309191.ref017","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1471-2334-12-103","article-title":"Point-of-care detection of lipoarabinomannan (LAM) in urine for diagnosis of HIV-associated tuberculosis: a state of the art review","volume":"12","author":"SD Lawn","year":"2012","journal-title":"BMC Infect Dis"},{"key":"pone.0309191.ref018","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.tube.2018.06.004","article-title":"Detection of lipoarabinomannan in urine and serum of HIV-positive and HIV-negative TB suspects using an improved capture-enzyme linked immuno absorbent assay and gas chromatography\/mass spectrometry","volume":"111","author":"AG Amin","year":"2018","journal-title":"Tuberculosis (Edinb)"},{"key":"pone.0309191.ref019","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12916-016-0603-9","article-title":"Detection of lipoarabinomannan (LAM) in urine is an independent predictor of mortality risk in patients receiving treatment for HIV-associated tuberculosis in sub-Saharan Africa: a systematic review and meta-analysis","volume":"14","author":"A Gupta-Wright","year":"2016","journal-title":"BMC Med"},{"issue":"4","key":"pone.0309191.ref020","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1097\/QAI.0000000000000672","article-title":"Underestimation of the true specificity of the urine lipoarabinomannan point-of-care diagnostic assay for HIV-associated tuberculosis","volume":"69","author":"SD Lawn","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"12","key":"pone.0309191.ref021","first-page":"e01234","article-title":"A novel sensitive immunoassay targeting the 5-methylthio-d-xylofuranose-lipoarabinomannan epitope meets the WHO\u2019s performance target for tuberculosis diagnosis","volume":"56","author":"G Sigal","year":"n.d","journal-title":"Journal of Clinical Microbiology"},{"issue":"4","key":"pone.0309191.ref022","doi-asserted-by":"crossref","first-page":"e0215443","DOI":"10.1371\/journal.pone.0215443","article-title":"Sensitive electrochemiluminescence (ECL) immunoassays for detecting lipoarabinomannan (LAM) and ESAT-6 in urine and serum from tuberculosis patients","volume":"14","author":"T Broger","year":"2019","journal-title":"PLoS One"},{"issue":"5","key":"pone.0309191.ref023","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41564-019-0380-2","article-title":"A systematic review of biomarkers to detect active tuberculosis","volume":"4","author":"E MacLean","year":"2019","journal-title":"Nat Microbiol"},{"key":"pone.0309191.ref024","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1186\/s12879-014-0655-4","article-title":"Urine lipoarabinomannan point-of-care testing in patients affected by pulmonary nontuberculous mycobacteria--experiences from the Danish Cystic Fibrosis cohort study","volume":"14","author":"T Qvist","year":"2014","journal-title":"BMC Infect Dis"},{"issue":"5","key":"pone.0309191.ref025","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.jcf.2020.06.016","article-title":"Urine lipoarabinomannan as a marker for low-risk of NTM infection in the CF airway","volume":"19","author":"P De","year":"2020","journal-title":"J Cyst Fibros"},{"key":"pone.0309191.ref026","article-title":"Urine lipoarabinomannan as a biomarker for Mycobacterium tuberculosis and non-tuberculous mycobacterial infections","author":"J Manzer","year":"2024","journal-title":"Protocolsio"},{"issue":"11","key":"pone.0309191.ref027","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.cell.2022.04.024","article-title":"Host and pathogen response to bacteriophage engineered against Mycobacterium abscessus lung infection","volume":"185","author":"JA Nick","year":"2022","journal-title":"Cell"},{"key":"pone.0309191.ref028","author":"V Lovell","year":"2020"},{"key":"pone.0309191.ref029","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jpeds.2016.09.064","article-title":"Diagnosis of cystic fibrosis: consensus guidelines from the cystic fibrosis foundation","author":"PM Farrell","year":"2017","journal-title":"J Pediatr"},{"issue":"7","key":"pone.0309191.ref030","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1513\/AnnalsATS.201511-781OC","article-title":"The cystic fibrosis foundation patient registry. Design and methods of a national observational disease registry","volume":"13","author":"E Knapp","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"pone.0309191.ref031","author":"R Khare","year":"2024"},{"issue":"12","key":"pone.0309191.ref032","doi-asserted-by":"crossref","first-page":"e0144088","DOI":"10.1371\/journal.pone.0144088","article-title":"Estimation of D-arabinose by gas chromatography\/mass spectrometry as surrogate for mycobacterial lipoarabinomannan in human urine","volume":"10","author":"P De","year":"2015","journal-title":"PLoS One"},{"key":"pone.0309191.ref033","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/978-1-59745-207-6_3","article-title":"Lipoglycans of Mycobacterium tuberculosis: isolation, purification, and characterization.","volume-title":"Mycobacteria Protocols","author":"L Shi","year":"2009"},{"key":"pone.0309191.ref034","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: Building an international community of software platform partners","volume":"95","author":"PA Harris","year":"2019","journal-title":"J Biomed Inform"},{"issue":"2","key":"pone.0309191.ref035","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"PA Harris","year":"2009","journal-title":"J Biomed Inform"},{"issue":"10212","key":"pone.0309191.ref036","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"HGM Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"pone.0309191.ref037","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"PG Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"pone.0309191.ref038","volume-title":"Cystic Fibrosis Foundation Patient Registry: 2023 Annual Data Report","author":"B Marshall","year":"2024"},{"issue":"3","key":"pone.0309191.ref039","doi-asserted-by":"crossref","first-page":"e1700171","DOI":"10.1183\/13993003.00170-2018","article-title":"Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement","volume":"51","author":"J van Ingen","year":"2018","journal-title":"Eur Respir J"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0309191","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T16:08:33Z","timestamp":1741622913000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0309191"}},"subtitle":[],"editor":[{"given":"Hideo","family":"Kato","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,3,10]]},"references-count":39,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0309191","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.08.08.24311698","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,10]]}}}